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Abstract.12




Objective: To prospectively examine the association between chronic obstructive pulmonary disease (COPD) and subclinical
impairments in lung function and the risk of dementia.
15
16
Methods: In the Rotterdam Study, we assessed the risk of incident dementia in participants with Preserved Ratio Impaired
Spirometry (PRISm; FEV1/FVC ≥ 0.7, FEV1 < 80%) and in participants with COPD (FEV1/FVC < 0.7) compared to those
with normal spirometry (controls; FEV1/FVC ≥ 0.7, FEV1 ≥ 80%). Hazard ratios (HRs) with 95% confidence intervals (CI)
for dementia were adjusted for age, sex, education attainment, smoking status, systolic blood pressure, body mass index,






Results: Of 4,765 participants, 110 (2.3%) developed dementia after 3.3 years. Compared to controls, participants with
PRISm, but not COPD, had an increased risk for all-type dementia (adjusted HRPRISm 2.70; 95% CI, 1.53–4.75; adjusted
HRCOPD 1.03; 95% CI, 0.61–1.74). These findings were primarily driven by men and smokers. Similarly, participants with
FVC% predicted values in the lowest quartile compared to those in the highest quartile were at increased risk of all-type






Conclusion: Participants with PRISm or a low FVC% predicted lung function were at increased risk of dementia, compared
to those with normal spirometry or a higher FVC% predicted, respectively. Further research is needed to elucidate whether
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INTRODUCTION 32
Dementia is characterized by poor cognitive per- 33
formance interfering with activities of daily living 34
and impaired health-related quality of life at older 35
ages [1], with an increasing prevalence worldwide 36
[2]. In order to mitigate the burden of dementia 37
through postponement or prevention, and to respond 38
adequately on such a major health problem, the 39
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identification of key modifiable risk factors is war-40
ranted and include smoking, obesity, hypertension,41
depression, sleep apnea, diabetes, and hyperlipidemia42
[3]. Chronic obstructive pulmonary disease (COPD)43
and decreased lung volume capacity have also been44
associated with a greater risk of dementia and com-45
promised cognitive ability [4]. Possible etiological46
links with dementia comprise systemic inflammation47
and hypoxia induced oxidative stress [4–6].48
More recently, preserved ratio impaired spirome-49
try (PRISm)—with a prevalence ranging from 3% to50
20% in adults [7]—has emerged as a clinically rele-51
vant entity related to premature mortality [7, 8], but52
thus far has been largely understudied, because of a53
hitherto stronger focus on COPD. The term PRISm54
encompasses the findings of restrictive respiratory55
pattern with impaired spirometry, i.e., decreased56
forced expiratory volume in one second (FEV1) or57
forced vital capacity (FVC) but preserved FEV1/FVC58
ratio [7]. People with PRISm suffer from lung func-59
tion restriction but due to normal range of FEV1/FVC60
ratio would not be diagnosed as COPD according to61
the GOLD guidelines in clinical practice [7, 9]. Pre-62
vious studies have suggested PRISm is a fluctuating63
state, serving as an intermediate phase between nor-64
mal spirometry and COPD [8, 10]. However, very65
little is known about the clinical sequelae of PRISm,66
including risk of dementia.67
Therefore, the aim of this study was to investi-68
gate the association of both COPD and subclinical69
reduced lung function, as evidenced by the pres-70
ence of impaired lung volumes (PRISm), with the71
risk of dementia at follow-up within a prospective72
population-based cohort study.73
METHODS74
This study was conducted within the Rotterdam75
Study, a prospective cohort study that started in 1990,76
comprising almost 15,000 participants aged at least77
45 years, with the aim of studying chronic diseases78
in the general population [11]. Every four to five79
years, participants underwent follow-up examina-80
tions, consisting of a home interview and various81
physical examinations at the research center. We used82
data collected between 2009 and 2014 as baseline83
for this study, when participants underwent spirom-84
etry at the research center. A total of 4,765 persons85
with interpretable spirometry and without asthma and86
without prevalent dementia were retained for analy-87
ses (Fig. 1).
Fig. 1. Flow chart for participants with interpretable spirometry at
baseline, informed consent for follow-up and graph for definition
of lung function categories.
Standard protocol approvals, registrations, and 88
patients consents 89
The study had been approved by the medical ethics 90
committee of the Erasmus Medical Centre (Rotter- 91
dam, the Netherlands), and the review board of the 92
Netherlands Ministry of Health, Welfare and Sports 93
(1068889-159521-PG). Informed consent was pro- 94
vided by all participants. 95
Spirometry test 96
Lung function was assessed via pre-bronchodilator 97
spirometry performed by trained paramedical person- 98
nel using a Master Screen PFT Pro (Care Fusion, 99
Netherlands) according to the American Thoracic 100
Society (ATS)/European Respiratory Society (ERS) 101
guidelines [12]. Predicted FVC and predicted FEV1 102
values were calculated using Global Lung Initiative 103
(GLI) reference equations taking age, sex, height, 104
and ethnicity into account [13]. Based on these val- 105
ues, the following subgroups were defined: COPD 106
(FEV1/FVC < 70%), PRISm (FEV1/FVC ≥ 70% and 107
FEV1 < 80% predicted), and normal spirometry 108
(FEV1/FVC ≥ 70% and an FEV1 ≥ 80% predicted) 109
were distinguished [7, 9]. Spirometry was conducted 110
in accordance with the ATS/ERS guidelines [12, 111
13], with specific preparatory instructions, e.g., with 112
respect to smoking or other factors. In order to guar- 113
antee the reliability and reproducibility, at least two 114
spirometry tests were implemented on each partici- 115
pant, and the best reading was obtained. No specific 116
preparatory instructions were given (e.g., related to 117
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lung function parameters were derived from values119
in this study, which is similar to quintile subgroups120
in a previous study [14]. For calculation of trend-121
ing hazard ratio with 10% change in lung function,122
lung function parameters were included in cox mod-123
els after being divided by 10. Airflow limitation124
was confirmed by the value of a post-bronchodilator125
FEV1/FVC below 0.7 [9].126
Dementia assessment127
Dementia assessment was conducted for partici-128
pants at baseline and subsequent center visits with129
the Mini-Mental State Examination and the Geriatric130
Mental Schedule [15]. Those with a Mini-Mental131
State Examination score < 26 or Geriatric Mental132
Schedule score > 0 underwent further investigation133
along with an interview with a research physi-134
cian, that contained the Cambridge Examination for135
Mental Disorders of the Elderly. The whole popu-136
lation also underwent routine cognitive assessment.137
Moreover, the entire cohort was continuously under138
surveillance for dementia through electronic link-139
age of the study database with medical records from140
general practitioners and the regional institute for141
outpatient mental health care. If available clinical142
neuroimaging was used for determining demen-143
tia subtype [11]. An adjudication panel led by a144
consultant neurologist established the final diag-145
nosis according to standard criteria for dementia146
(Diagnostic and Statistical Manual of Mental Dis-147
order, Third Edition-Revised: DSM-III-R) and AD148
(National Institute of Neurological and Communica-149
tive Disorders and Stroke-Alzheimer’s Disease and150
Related Disorders Association: NINCDS–ADRDA).151
Follow-up until 14 December 2017 was virtually152
complete (95.5% of potential person-years). Within153
this period, participants were followed until the date154
of dementia and AD diagnosis, death, loss to follow-155
up or 14 December 2017, whichever came first.156
Covariates157
The following variables were considered as pos-158
sible confounders, primarily based on previous159
literature and their role as shared causes between lung160
function and dementia. Demographic information161
included age, sex, education level (primary educa-162
tion, lower education, intermediate education, higher163
education), smoking status (never, former, current),164
systolic blood pressure (mmHg), body mass index165
(BMI, kg/m2, calculated by weight [kg] divided by166
height [m] squared), and chronic comorbid condi- 167
tions (diabetes and stroke) [11]. Blood samples were 168
extracted for determination of levels of triglycerides 169
and DNA at the research center. Apolipoprotein E 170
(APOE) genotype was determined using a PCR in 171
the original cohort (RS-I, starting between July 1989 172
and September 1993) and a bi-allelic TaqMan assay 173
(rs7412 and rs429358) on labeled DNA samples in 174
the two cohorts (RS-II-3, starting between Febru- 175
ary 2000 and December 2001; and RS-III-2, starting 176
between February 2006 and December 2008), respec- 177
tively. This study included these three sub-cohorts. 178
APOE 4 represented carrier of one or two 4 alle- 179
les. Participants were categorized into three groups: 180
high genetic risk (2/4, 3/4, or 4/4 genotypes), 181
intermediate risk (3/3), or low risk (2/2 or 2/3) 182
[16]. As the strongest genetic risk factor for dementia, 183
APOE has additionally potent cardiovascular effects, 184
including arteriosclerosis and cardiac function. In this 185
regard, APOE may also impact lung function. We 186
therefore included APOE in the models as possible 187
confounder [14, 17]. Missing values were handled by 188
five-times imputation using chained equation [18]. 189
Statistical analysis 190
Baseline characteristics are described among sub- 191
groups of lung function. Data are expressed as 192
mean ± standard deviation (SD) for normally dis- 193
tributed variables or as median (interquartile range 194
[IQR]) for non-normally distributed variables. 195
For analyses of the association between lung func- 196
tion at baseline and risk of incident dementia, we 197
used Cox proportional-hazards regression analyses. 198
Lung function was categorized as normal spirom- 199
etry, PRISm, and COPD. In addition, lung volume 200
capacity comprised subgroups of quartiles of FEV1% 201
predicted, FVC% predicted and ratio of FEV1/FVC. 202
Follow-up time started on the date of spirometry 203
test at baseline and ended until diagnosis of demen- 204
tia, death, lost to follow-up, or December 14, 2017. 205
The proportional hazards assumption was checked 206
using Schoenfeld residuals. Model 1 was adjusted 207
for APOE category, age, sex, and education level. 208
Model 2 was additionally adjusted for smoking sta- 209
tus, BMI, systolic blood pressure, triglyceride, and 210
comorbidity (history of stroke and diabetes mellitus). 211
Covariates above were selected based on previous 212
literature knowledge, clinical relevance and availabil- 213
ity of the data. Given the relatively small number 214
of incident cases of dementia, we also constructed 215
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Table 1
Baseline characteristics of participants, stratified by lung function category
Normal PRISm COPD p
n (%) 3683 (77.3) 319 (6.7) 763 (16.0) -
Age, y 67.8 (12.5) 68.6 (14.4) 70.6 (13.4) < 0.001
Female, (%) 2120 (57.6) 171 (53.6) 324 (42.5) < 0.001
Education level
Primary education 246 (6.8) 31 (9.9) 81 (10.7) < 0.001
lower education 1445 (39.7) 117 (37.1) 279 (36.9)
Intermediate education 1089 (29.8) 93 (29.5) 249 (32.9)
Higher education 864 (23.7) 74 (23.5) 148 (19.6)
Smoking status, (%)
Never 1383 (37.6) 97 (30.4) 135 (17.7) < 0.001
Former 1960 (53.2) 177 (55.5) 415 (54.4)
Current 340 (9.2) 45 (14.1) 213 (27.9)
Systolic pressure 141 (29) 142 (29) 142 (26) 0.369
Body mass index, kg/m2 27.0 (5.0) 28.4 (5.9) 26.1 (5.0) < 0.001
Triglycerides, mg/dl 1.3 (0.7) 1.4 (0.9) 1.2 (0.7) < 0.001
History of stroke 34 (0.9) 7 (2.2) 12 (1.6) 0.040∗
History of diabetes mellitus 292 (8.0) 31 (10.0) 73 (9.7) 0.200
Apolipoprotein E genotype, (%)
4-allele positive 937 (27.3) 66 (22.8) 196 (27.8) 0.142
4-allele negative 2496 (72.7) 224 (77.2) 509 (72.2)
FEV1/FVC 78.7 (6.4) 76.1 (7.1) 65.6 (7.6) < 0.001
FEV1% predicted 103.2 (18.7) 73.8 (10.6) 79.1 (24.7) < 0.001
FVC% predicted 101.2 (17.9) 72.2 (11.7) 94.0 (24.9) < 0.001
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced
vital capacity; PRISm, preserved ratio impaired spirometry. Data represent original data without imputed values.
Missing values were present for education attainment (1.0%), systolic blood pressure (2.8%), triglyceride (1.7%),
and history of diabetes (7.1%). ∗Fisher’s exact test.
for using propensity scores. Propensity scores were217
employed to reduce the number of covariates through218
summarizing information of variables into a single219
score, thus avoiding any problem of overfitting the220
models [19, 20]. In this study, propensity scores are221
the predicted probabilities of PRISm and COPD and222
derived by fitting logistic regression models adjusting223
for age, sex, education level, smoking status, systolic224
blood pressure, BMI, triglycerides, chronic comorbid225
conditions (diabetes and stroke), and APOE pheno-226
types.227
We also studied how PRISm and COPD related228
to the risk of mortality to gauge the possible effect229
of competing risk in our associations. The compet-230
ing risk, such as death before occurrence of incident231
dementia, are considered as independent event but is232
neglected in conventional methods for survival anal-233
yses, thus the true observation of the event of interest234
could be hindered in the presence of competing risk235
and then distort the association we explored [21].236
For unadjusted survival analyses intended to por-237
tray absolute risks, we used sub-distribution hazard238
models to account for competing risks to estimate239
cumulative incidence of dementia and all-cause death240
[22].
In addition, we conducted stratified analyses in 241
women, men, non-smoking participants, smokers and 242
participants without APOE 4 allele and history of 243
stroke and diabetes. These were selected as possi- 244
ble effect modifiers based on previous literature and 245
biological plausibility [3, 23–27]. 246
RESULTS 247
Clinical and lung functional characteristics of 248
participants 249
Among 4,765 participants (mean age 68.2 ± 12.9 250
years, 54.9% women), 16.0% (n = 763) had COPD, 251
6.7% (n = 319) had PRISm, and 77.3% (n = 3683) 252
had normal spirometry. More than twenty percent 253
(23.0%) of the participants received higher edu- 254
cation, and two thirds (66.1%) were current or 255
former smokers. The participants had a median 256
BMI of 27.0 ± 5.1 Kg/m2, systolic blood pres- 257
sure of 141 ± 29.0 mmHg, and triglyceride level of 258
1.3 ± 0.8 mg/dl. While 8.4% (n = 396) had a history 259
of diabetes mellitus, 1.1% of them experienced stroke 260
before (n = 53). 1,199 (27.1%) participants carried 261
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Table 2
Lung function category and risk of dementia
All-type dementia
cases/death/N FU, years HR1 (95% CI) HR2 (95% CI) HR3 (95% CI)
Normal 75/179/3683 3.3 (1.6) 1.0 1.0 1.0
PRISm 15/25/319 3.4 (1.6) 2.42 (1.38;4.24) 2.70 (1.53;4.75) 2.47 (1.40;4.35)
COPD 20/88/763 3.4 (1.6) 1.06 (0.63;1.77) 1.03 (0.61;1.74) 1.08 (0.63;1.83)
AD
cases/death/N FU, years HR1 (95% CI) HR2 (95% CI) HR3 (95% CI)
Normal 65/179/3673 3.3 (1.6) 1.0 1.0 1.0
PRISm 9/25/313 3.4 (1.6) 1.70 (0.84;3.43) 1.87 (0.92;3.81) 1.74 (0.86;3.54)
COPD 15/88/758 3.4 (1.6) 0.89 (0.49;1.60) 0.87 (0.48;1.59) 0.89 (0.49;1.63)
AD, Alzheimer’s disease; COPD, chronic obstructive pulmonary disease; CI, confidence interval; FU, follow-
up; HR, hazard ratio; PRISm, preserved ratio impaired spirometry; Model 1, Cox regression adjusted for APOE
genotype, age, sex, and education level; Model 2, Model 1 plus adjustment smoking status, BMI, systolic blood
pressure, triglycerides, and history of comorbidities (stroke and diabetes mellitus); Model 3, Cox regression adjusted
for propensity scores∗, age, and sex. ∗Propensity scores was calculated with age, sex, education level, smoking
status, BMI, systolic blood pressure, triglyceride, history of comorbidities (stroke and diabetes mellitus) and APOE
genotype; follow-up time started after spirometry at baseline.
Lung function and risk of incident262
dementia and AD263
During a median of 3.3 years of follow-up, 110264
participants (2.3%) developed incident dementia, of265
whom 89 (1.9%) developed AD. Moreover, among266
all participants, 292 (6.1%) died due to non-dementia267
related causes within the follow-up period (Table 2).268
First, we evaluated the association between lung269
function impairment at baseline and risk of incident270
dementia. As shown in Table 2, higher proportion of271
participants with PRISm developed dementia com-272
pared to participants with normal spirometry, while273
COPD patients did not. Compared with participants274
with normal spirometry, participants with PRISm275
exhibited a higher risk of all-type dementia (Model276
2 hazard ratio [HR], 2.70; 95% confidence interval277
[CI], 1.53–4.75), while subjects with COPD did not278
(HR2, 1.03; 95% CI, 0.61–1.74), after accounting for279
all covariates. After being adjusted for propensity280
score, age and sex, results of model 3 were similar281
to model 2 (Table 2). Hazard ratios of association of282
PRISm and COPD with all-type dementia were 2.47283
(95% CI, 1.40–4.35) and 1.08 (95% CI, 0.63–1.83),284
respectively.285
Concurrently, participants with PRISm were also286
at increased risk of AD, albeit this did not reach sta-287
tistical significance (HR2, 1.87; 95% CI, 0.92–3.81).288
COPD was not significantly associated with AD289
(HR2, 0.87; 95% CI, 0.48–1.59) (Table 2).290
We also investigated the risk of developing demen-291
tia associated with lower lung function by using292
continuous parameters (FEV1%, FVC%, FEV1/293
FVC%) and their categorized quartiles (Fig. 2). A 294
lower value in FEV1% predicted was associated with 295
an elevated risk of all-type dementia (HR2, 1.12; 95% 296
CI, 1.02–1.23). Relative to participants with the high- 297
est FVC% predicted values (Quartile 4), those with 298
the lowest FVC% predicted values (Quartile 1) were 299
at increased risk of both all-type dementia (Model 300
2 hazard ratio [HR2], 2.28; 95% confidence inter- 301
val [CI], 1.31–3.98) and AD (HR2, 2.13; 95% CI, 302
1.13–4.02), after accounting for demographics and 303
APOE genotypes. A lower value in FVC% predicted 304
was significantly associated with an increased risk 305
of both all-type dementia and AD in all models. 306
FEV1/FVC was not associated with dementia risk in 307
any model (Fig. 2). 308
Moreover, a competing risk model was used to 309
measure the competing risk of mortality during the 310
follow-up period on the observation of dementia 311
events. Although participants with PRISm suffered 312
from higher cumulative incidence of all-cause mor- 313
tality than participants with normal spirometry, 314
participants with PRISm still exhibited significantly 315
higher cumulative incidence of all-type dementia 316
(p = 0.018), but not of AD (p > 0.05) (Supplementary 317
Figure 1). 318
Stratified analysis 319
Methods and figures on the stratified analyses are 320
presented in the Supplementary Material. Regarding 321
the association between COPD or PRISm and the 322
risk of incident dementia, stratified analyses were 323
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Fig. 2. Respiratory indexes (FEV1% predicted, FVC % predicted and FEV1/FVC ratio) and risk of dementia (A) and Alzheimer’s disease (B).
AD, Alzheimer’s disease; A, All-type dementia; B, Alzheimer’s disease; CI, confidence interval; HR, hazard ratio; FEV1, Forced Expiratory
volume in one second; FVC, forced vital capacity; HR1, HR from Cox Proportional-Hazard regression analysis adjusted for APOE genotype,
age, sex, and education level; HR2, HR1 with additional adjustment for current or ever smoking, BMI, systolic blood pressure, triglyceride,
and history of comorbidities (stroke and diabetes mellitus). Participants in the highest percentile (Quartile 4) of spirometry indexes were
regarded as reference group (hidden). ∗follow-up time start after spirometry at baseline.
participants, participants without history of stroke325
and diabetes, and APOE 4 non-carriers. Significant326
associations were found between PRISm and all-327
type dementia in men (adjusted HR = 5.29, 95% CI,328
2.40–11.65), but not in women (adjusted HR = 1.65,329
95% CI, 0.71–3.87); current or former smokers330
(adjusted HR = 3.36, 95% CI, 1.71–6.60), but not331
in never-smoking participants (adjusted HR = 1.95,332
95% CI, 0.68–5.57); participants without a history of333
stroke (adjusted HR = 2.58, 95% CI, 1.45–4.59) and 334
diabetes (adjusted HR = 2.56, 95% CI, 1.38-4.78); 335
and participants without APOE 4 allele (HR = 1.56, 336
95% CI, 0.71–3.45). Significant association between 337
PRISm and AD risk were only observed among men 338
(Supplementary Figure 2). 339
We have tested the effect of interaction of lung 340
function and sex, and interaction of lung function and 341
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tests for multiplicative interaction. These tests of343
interaction did not reach statistical significance (data344
not shown).345
In addition, Supplementary Figure 3 shows the346
association between continuous spirometry param-347
eters with the risk of newly diagnosed dementia348
(Supplementary Figure 3A) or newly diagnosed349
AD (Supplementary Figure 3B), stratified by sex,350
smoking status and absence of stroke, diabetes,351
and APOE 4 non-carriers. A lower FEV1% pre-352
dicted was associated with a greater risk of all-type353
dementia only among women, never-smoking partic-354
ipants, and those without prior stroke, but not among355
men, current or former smoking participants, and356
participants without prior diabetes and APOE 4 non-357
carriers. A lower FVC% predicted was associated358
with an increased risk of all-type dementia among359
all subgroups except APOE 4 non-carriers. Statis-360
tical significance was not found between decreased361
FEV1/FVC and risk of all-type dementia. Regarding362
elevated risk of AD, reduced FVC% predicted and363
FEV1/FVC elevated were associated with AD among364
women, nonsmokers and those without prior stroke,365
while FEV1% predicted did not show an increased366
risk of AD among those without prior stroke.367
DISCUSSION368
In this population-based cohort study, individu-369
als with PRISm were at increased risk of all-type370
dementia, while those with COPD were not. Espe-371
cially, predicted FVC% was strongly associated with372
a higher risk of dementia among the whole study373
population.374
The main finding of this study is that PRISm375
was associated with an increased risk of dementia.376
Comorbidities, such as diabetes and stroke, are more377
common among participants of this restrictive lung-378
function pattern [28], and may confound the link with379
impaired cognition and the increased risk for demen-380
tia. However, while we found a higher prevalence of381
prior stroke in participants with PRISm, the associ-382
ation between PRISm and dementia persisted after383
adjusting for these comorbidities. There are several384
possible mechanisms linking PRISm with dementia.385
Firstly, ambient pollution and inhalational exposures386
are associated with higher risk of PRISm [29], which387
could also contribute to the development of dementia388
[30, 31]. For example, fine particulate matter in air389
could not only lead to impaired lung function through390
disturbing alveolarization process and altering lung391
elastance at an earlier life stage [32], but also be linked 392
to higher dementia risk via accumulation of A42 and 393
alteration on neuroinflammation and brain immune 394
response, as exposure to certain level of air pollu- 395
tion could upregulate expression of mRNA COX2 396
and IL-1 in olfactory bulb, disrupt tight junctions in 397
frontal blood-brain barrier and activate nuclear NFκB 398
in brain endothelial cells [31, 33]. 399
Secondly, some studies reported that FVC decline 400
in subjects with PRISm was accompanied with sys- 401
temic inflammation [34–36]. Systemic inflammation 402
in turn may be linked with cognitive impairment and/ 403
or occurrence of dementia [37]. Serum inflammatory 404
cytokines, like (IL)-18, IL-1 receptor antagonist and 405
IL-6, have been linked with AD [38], and high lev- 406
els of serum IL-6 were associated with a greater risk 407
of non-AD dementia as well [39]. Unfortunately, we 408
did not have inflammatory markers available in this 409
population to test this hypothesis. 410
Thirdly, reduced lung function could limit peak 411
oxygen uptake and oxygen saturation, resulting in 412
potential hypoxia [6, 40, 41]. In turn, hypoxia has 413
been reported to induce cognitive deficiency and 414
dementia in both human and animal studies [42, 415
43]. Mice with hypoxia exhibited tau hyperphos- 416
phorylation, A upregulation, and dysfunction of 417
neurotransmitter system [43]. 418
In stratified analyses, we found that the association 419
between PRISm and dementia was present in men, 420
current and past smokers, and participants without 421
history of stroke and diabetes. 422
Though speculative, sex differences can poten- 423
tially be explained by unmeasured confounding by 424
sex hormones [44, 45]. Indeed, estrogen has protec- 425
tive effects on systemic and cerebrovascular athero- 426
sclerosis, which in turn impact both lung function 427
and dementia risk [24, 44]. In this population-based 428
study, we could not corroborate this speculation and 429
future research is therefore needed to explore these 430
hypotheses further. 431
The effect modification by smoking status indi- 432
cates that the effect of poor lung function on risk of 433
dementia is further aggravated in presence of smok- 434
ing. This may be related to direct toxic effects of 435
smoking in the brain, for instance increased levels of 436
oxidants and free radical species, which promotes for- 437
mation of senile plaque and neurofibrillary tangles. In 438
turn, these pathological processes may interact with 439
cerebral hypoxia and hypoperfusion due to poor lung 440
function [46, 47]. 441
With respect to stroke, APOE 4 carriership and 442
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largest stratum and found that associations among444
persons without stroke, APOE 4 non-carriers, and445
non-diabetics remained largely similar to the overall446
population.447
Among continuous lung function parameters,448
FVC% predicted, but not FEV1/FVC ratio or FEV1%449
predicted, was significantly associated with both all-450
type dementia and AD risk. Previous studies have451
varyingly reported on FEV1, FEV1/FVR ratio, or452
FVC% predicted to be associated with dementia.453
Heterogeneity across study population, including454
differences in age-range, sampling strategy and co-455
morbid conditions may explain differences in the456
strength of associations of the various parameters457
with dementia.458
We did not demonstrate an association between459
COPD and the risk of dementia, in contrast to the prior460
study [14]. Previously, we found participants with461
PRISm and COPD to suffer from increased all-cause462
and cardiovascular mortality [7], and similarly the463
present competing risk model suggested the highest464
figure of all-cause mortality in COPD group. There-465
fore, mortality may hinder the occurrence of incident466
dementia during the follow-up period.467
Strengths and limitations468
An important strength of this study is the rela-469
tively large number of elderly participants included470
for assessment of the lung function through standard-471
ized protocols and dementia data based on continuous472
follow-up. Competing risks is a limitation when473
using traditional cox proportion-hazard regression474
analyses. However, we used competing risk model475
to calculate cumulative risk of dementia to correct476
effect of variable of interest. The small number of477
incident dementia cases limited our study power,478
but we applied propensity scores to avoid poten-479
tial overfitting problem with adjustment for extensive480
covariates.481
CONCLUSIONS482
As a conclusion, among this community-dwelling483
population, participants with PRISm or participants484
with a low FVC% predicted lung function were at485
increased risk of dementia, compared to those with486
normal spirometry or a higher FVC% predicted,487
respectively. Further research is needed to elucidate488
whether this association is causal and how PRISm489
might contribute to dementia pathogenesis. There-490
fore, it is necessary to recognize PRISm and evaluate491
status of FVC% predicted when conducting spirom- 492
etry tests in clinical settings. 493
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